Anna Maria Carvalhas Gabrielli, Francesca Ferretti, Camilla Maria Monico, Enrico Tombetti, Giovanni Maconi, Samanta Romeo, Nicole Piazza O Sed, Flavio Caprioli, Anna Maria Mazzola, Saverio Alicante, Roberto Bertè, Elisabetta Lolli, Maria Lia Scribano, Elisabetta Buscarini, Chiara Ricci, Stefania Carmagnola, Sandro Ardizzone, Rosanna Cannatelli
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor recently approved to induce and maintain remission in ulcerative colitis (UC). AIMS: Considering the number of anti-TNF non-responders, this study aims to assess the effectiveness and safety of tofacitinib in a cohort of multi-failure patients with moderate-to-severe UC at 52 weeks. METHODS: From January 2021 to March 2023, we performed a prospective multicenter study observing adult patients with moderate-to-severe UC starting tofacitinib after an anti-TNF failure for a 52-week-long period...
March 26, 2024: Digestive Diseases and Sciences